Liminatus Pharma agreed to pay shares worth $320 million to acquire InnocsAI, adding an early CAR-T pipeline including IBC101, an autologous CD19xCD22 bivalent program targeting relapsed or refractory B-cell malignancies. InnocsAI already has FDA clearance to begin a Phase 1/2 study in Korea, and the deal also includes a preclinical bicistronic CAR-T concept (INC101) plus an anti-CS1 antibody module intended for a trivalent framework.